CNBX · CNBX Pharmaceuticals Inc. · Debt
$0.00
+0.00 (+0.00%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jun 24, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the Company has incurred a net loss of $311,982 for the nine months ended May 31, 2026, it has incurred cumulative losses since inception of $25,580,358. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.”View the 10-Q filed Jun 24, 2026
Market Cap
$160,576
Shares
1.61B
Volume · Oct 5
855.25K
Avg daily vol (3M)
8.11M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of convertible notes payable | 2026-05-31 | USD 1,047,204 | 10-Q filed 2026-06-24 |
| Short-term borrowings | 2026-05-31 | USD 120,000 | 10-Q filed 2026-06-24 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.